You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Oncology
Lupin and Natco secure US FDA approval for generic Eribulin Mesylate Injection
Login
Username:

Password:


Related Headlines

Anixa secures Canadian patent milestone for ovarian cancer vaccine

Rallybio and Avenzo Therapeutics announce merger agreement and USD215m financing

IBA launches Cyclone iKure for industrial-scale Astatine-211 production

Circio and GenAssist announce gene therapy research collaboration for muscle diseases and in vivo cell therapy

Avacta reports encouraging early efficacy signals for AVA6000 in salivary gland cancer at ASCO 2026

Dizal presents positive NSCLC data for DZD6008 and golidocitinib at ASCO 2026

TiumBio presents Phase 2a interim data for Tosposertib plus pembrolizumab at ASCO 2026

ImmVira reports 100% CRR at 9 months in bladder carcinoma in situ with MVR-T3011

CARsgen presents long-term satri-cel follow-up results at 2026 ASCO Annual Meeting

AstraZeneca secures US approval for Imfinzi–BCG regimen in high‑risk bladder cancer

Whitehawk Therapeutics to present at Jefferies 2026 Global Healthcare Conference

Innovent Biologics and Pfizer agree global collaboration to develop innovative oncology medicines

Phanes Therapeutics reports updated Phase 2 results for spevatamig (PT886) in combination with chemotherapy

CellCarta partners with Sonic Healthcare to commercialise companion diagnostics through Lab Network

Antengene receives Chinese clearance for Phase III study of ATG-022 in CLDN18.2+ advanced gastric/GEJ cancer

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026